Catherine L. Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine L. Kennedy has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Dena Lyras
Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Australia
6 shared publications - Julian I. Rood
Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, Monash University, Victoria, Australia
6 shared publications - Brendan John Jenkins
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia
5 shared publications John J. Emmins
Department of Immunology, Monash University, Prahan, Victoria 3004, Australia
5 shared publications- Elizabeth L. Hartland
Hudson Institute of Medical Research
4 shared publications Andrew I. Webb
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Melbourne, Australia
3 shared publications
Latest Publications
- 14 March 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (6) , 1459-1472
Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer
Purpose: The majority of gastric cancer patients are diagnosed with late-stage disease, for which distinct molecular subtypes have been identified that are potentially amenable to targeted therapies. However, there exists no molecular classification system with prognostic power for early-stage gastric cancer (EGC) because the molecular events promoting gastric cancer initiation remain ill-defined. Experimental Design: miRNA microarrays were performed on gastric tissue from the gp130F/F preclinical EGC mouse model, prior to tumor initiation. Computation prediction algorithms were performed on multiple data sets and independent gastric cancer patient cohorts. Quantitative real-time PCR expression profiling was undertaken in gp130F/F-based mouse strains and human gastric cancer cells genetically engineered for suppressed activation of the oncogenic latent transcription factor STAT3. Human gastric cancer cells with modulated expression of the miR-200 family member miR-429 were also assessed for their proliferative response. Results: Increased expression of miR-200 family members is associated with both tumor initiation in a STAT3-dependent manner in gp130F/F mice and EGC (i.e., stage IA) in patient cohorts. Overexpression of miR-429 also elicited contrasting pro- and antiproliferative responses in human gastric cancer cells depending on their cellular histologic subtype. We also identified a miR-200 family–regulated 15-gene signature that integrates multiple key current indicators of EGC, namely tumor invasion depth, differentiation, histology, and stage, and provides superior predictive power for overall survival compared with each EGC indicator alone. Conclusions: Collectively, our discovery of a STAT3-regulated, miR-200 family–associated gene signature specific for EGC, with predictive power, provides a molecular rationale to classify and stratify EGC patients for endoscopic treatment. Clin Cancer Res; 24(6); 1459–72. ©2018 AACR.
- 14 March 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (6) , 1459-1472
Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer
Purpose: The majority of gastric cancer patients are diagnosed with late-stage disease, for which distinct molecular subtypes have been identified that are potentially amenable to targeted therapies. However, there exists no molecular classification system with prognostic power for early-stage gastric cancer (EGC) because the molecular events promoting gastric cancer initiation remain ill-defined. Experimental Design: miRNA microarrays were performed on gastric tissue from the gp130F/F preclinical EGC mouse model, prior to tumor initiation. Computation prediction algorithms were performed on multiple data sets and independent gastric cancer patient cohorts. Quantitative real-time PCR expression profiling was undertaken in gp130F/F-based mouse strains and human gastric cancer cells genetically engineered for suppressed activation of the oncogenic latent transcription factor STAT3. Human gastric cancer cells with modulated expression of the miR-200 family member miR-429 were also assessed for their proliferative response. Results: Increased expression of miR-200 family members is associated with both tumor initiation in a STAT3-dependent manner in gp130F/F mice and EGC (i.e., stage IA) in patient cohorts. Overexpression of miR-429 also elicited contrasting pro- and antiproliferative responses in human gastric cancer cells depending on their cellular histologic subtype. We also identified a miR-200 family–regulated 15-gene signature that integrates multiple key current indicators of EGC, namely tumor invasion depth, differentiation, histology, and stage, and provides superior predictive power for overall survival compared with each EGC indicator alone. Conclusions: Collectively, our discovery of a STAT3-regulated, miR-200 family–associated gene signature specific for EGC, with predictive power, provides a molecular rationale to classify and stratify EGC patients for endoscopic treatment. Clin Cancer Res; 24(6); 1459–72. ©2018 AACR.
- 11 January 2018
- Published by Springer Nature
- Vol. 1725, 77-89
Citrobacter rodentium Infection Model for the Analysis of Bacterial Pathogenesis and Mucosal Immunology
Citrobacter rodentium is a mouse restricted pathogen that was originally isolated from laboratory mouse colonies and causes transmissible colonic hyperplasia, characterized by thickening of the colon and inflammation. As a natural pathogen of mice, the infection model has proven critical to the development of our understanding of the pathogenesis of enteric disease and the mucosal immune response. In addition to this, some features of disease such as dysbiosis, inflammation, and wound healing replicate features of human inflammatory bowel diseases. As such, the C. rodentium infection model has become a key tool in investigations of many aspects of mucosal immunology.
- 11 January 2018
- Published by Springer Nature
- Vol. 1725, 77-89
Citrobacter rodentium Infection Model for the Analysis of Bacterial Pathogenesis and Mucosal Immunology
Citrobacter rodentium is a mouse restricted pathogen that was originally isolated from laboratory mouse colonies and causes transmissible colonic hyperplasia, characterized by thickening of the colon and inflammation. As a natural pathogen of mice, the infection model has proven critical to the development of our understanding of the pathogenesis of enteric disease and the mucosal immune response. In addition to this, some features of disease such as dysbiosis, inflammation, and wound healing replicate features of human inflammatory bowel diseases. As such, the C. rodentium infection model has become a key tool in investigations of many aspects of mucosal immunology.
- Open Access
- 1 October 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (42) , 17337-17350
The bacterial arginine glycosyltransferase effector NleB preferentially modifies Fas-associated death domain protein (FADD)
- 1 October 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (42) , 17337-17350
Open AccessThe bacterial arginine glycosyltransferase effector NleB preferentially modifies Fas-associated death domain protein (FADD)
- Open Access
- 17 March 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 6442
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production
Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the production of pro-inflammatory cytokines through activating NF-κB and MAP kinases. Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine production in vitro and in vivo and ameliorates experimental autoimmune encephalomyelitis in mice. Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.
- 17 March 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 6442
Open AccessA RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production
Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the production of pro-inflammatory cytokines through activating NF-κB and MAP kinases. Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine production in vitro and in vivo and ameliorates experimental autoimmune encephalomyelitis in mice. Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.
- 1 February 2015
- Published by Elsevier in Atherosclerosis
- Vol. 238 (2) , 321-328
Imbalanced gp130 signalling in ApoE-deficient mice protects against atherosclerosis
- 1 February 2015
- Published by Elsevier in Atherosclerosis
- Vol. 238 (2) , 321-328
Imbalanced gp130 signalling in ApoE-deficient mice protects against atherosclerosis
- 3 December 2014
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 97 (2) , 321-326
Fas regulates neutrophil lifespan during viral and bacterial infection
The regulation of neutrophil lifespan is critical for a circumscribed immune response. Neutrophils are sensitive to Fas/CD95 death receptor signaling in vitro, but it is unknown if Fas regulates neutrophil lifespan in vivo. We hypothesized that FasL-expressing CD8+ T cells, which kill antigen-stimulated T cells during chronic viral infection, can also induce neutrophil death in tissues during infection. With the use of LysM-Cre Fasfl/fl mice, which lack Fas expression in macrophages and neutrophils, we show that Fas regulates neutrophil lifespan during lymphocytic choriomeningitis virus (LCMV) infection in the lung, peripheral blood, and spleen. Fas also contributed to the regulation of neutrophil numbers in the colon of Citrobacter rodentium-infected mice. To examine the effects of infection on Fas activation in neutrophils, we primed neutrophils with TLR ligands or IL-18, resulting in ablation of Fas death receptor signaling. These data provide the first in vivo genetic evidence that neutrophil lifespan is controlled by death receptor signaling and provide a mechanism to account for neutrophil resistance to Fas stimulation during infection.
- 3 December 2014
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 97 (2) , 321-326
Fas regulates neutrophil lifespan during viral and bacterial infection
The regulation of neutrophil lifespan is critical for a circumscribed immune response. Neutrophils are sensitive to Fas/CD95 death receptor signaling in vitro, but it is unknown if Fas regulates neutrophil lifespan in vivo. We hypothesized that FasL-expressing CD8+ T cells, which kill antigen-stimulated T cells during chronic viral infection, can also induce neutrophil death in tissues during infection. With the use of LysM-Cre Fasfl/fl mice, which lack Fas expression in macrophages and neutrophils, we show that Fas regulates neutrophil lifespan during lymphocytic choriomeningitis virus (LCMV) infection in the lung, peripheral blood, and spleen. Fas also contributed to the regulation of neutrophil numbers in the colon of Citrobacter rodentium-infected mice. To examine the effects of infection on Fas activation in neutrophils, we primed neutrophils with TLR ligands or IL-18, resulting in ablation of Fas death receptor signaling. These data provide the first in vivo genetic evidence that neutrophil lifespan is controlled by death receptor signaling and provide a mechanism to account for neutrophil resistance to Fas stimulation during infection.
- Open Access
- 11 September 2013
- Published by Springer Nature in Nature
- Vol. 501 (7466) , 247-251
A type III effector antagonizes death receptor signalling during bacterial gut infection
Colonizing enteric bacteria are shown to inhibit the antimicrobial process of host cell apoptosis through the action of NleB1, a type III secretion system effector with N-acetylglucosamine transferase activity, which can bind and modify eukaryotic death-domain-containing proteins. Previous studies identified a group of effectors from enteropathogenic Escherichia coli that can inhibit host nuclear factor-κB (NF-κB) signalling, yet only one of them, known as NleB, is required for bacterial virulence in vivo. Two papers published in this issue demonstrate the unique mechanism of action of NleB. It directly targets death receptor signalling complexes, binding to the death domains (DDs) of multiple DD-containing proteins including the TNF receptor, FAS, RIPK1, TRADD and FADD. NleB is shown to function as an N-acetylglucosamine (GlcNAc) transferase that modifies a conserved DD arginine, blocking the receptor-adapter interaction. These findings suggest that GlcNAc modification is essential for bacterial virulence and can regulate death receptor signalling. Successful infection by enteric bacterial pathogens depends on the ability of the bacteria to colonize the gut, replicate in host tissues and disseminate to other hosts. Pathogens such as Salmonella, Shigella and enteropathogenic and enterohaemorrhagic (EPEC and EHEC, respectively) Escherichia coli use a type III secretion system (T3SS) to deliver virulence effector proteins into host cells during infection that promote colonization and interfere with antimicrobial host responses1,2,3. Here we report that the T3SS effector NleB1 from EPEC binds to host cell death-domain-containing proteins and thereby inhibits death receptor signalling. Protein interaction studies identified FADD, TRADD and RIPK1 as binding partners of NleB1. NleB1 expressed ectopically or injected by the bacterial T3SS prevented Fas ligand or TNF-induced formation of the canonical death-inducing signalling complex (DISC) and proteolytic activation of caspase-8, an essential step in death-receptor-induced apoptosis. This inhibition depended on the N-acetylglucosamine transferase activity of NleB1, which specifically modified Arg 117 in the death domain of FADD. The importance of the death receptor apoptotic pathway to host defence was demonstrated using mice deficient in the FAS signalling pathway, which showed delayed clearance of the EPEC-like mouse pathogen Citrobacter rodentium and reversion to virulence of an nleB mutant. The activity of NleB suggests that EPEC and other attaching and effacing pathogens antagonize death-receptor-induced apoptosis of infected cells, thereby blocking a major antimicrobial host response.
- 11 September 2013
- Published by Springer Nature in Nature
- Vol. 501 (7466) , 247-251
Open AccessA type III effector antagonizes death receptor signalling during bacterial gut infection
Colonizing enteric bacteria are shown to inhibit the antimicrobial process of host cell apoptosis through the action of NleB1, a type III secretion system effector with N-acetylglucosamine transferase activity, which can bind and modify eukaryotic death-domain-containing proteins. Previous studies identified a group of effectors from enteropathogenic Escherichia coli that can inhibit host nuclear factor-κB (NF-κB) signalling, yet only one of them, known as NleB, is required for bacterial virulence in vivo. Two papers published in this issue demonstrate the unique mechanism of action of NleB. It directly targets death receptor signalling complexes, binding to the death domains (DDs) of multiple DD-containing proteins including the TNF receptor, FAS, RIPK1, TRADD and FADD. NleB is shown to function as an N-acetylglucosamine (GlcNAc) transferase that modifies a conserved DD arginine, blocking the receptor-adapter interaction. These findings suggest that GlcNAc modification is essential for bacterial virulence and can regulate death receptor signalling. Successful infection by enteric bacterial pathogens depends on the ability of the bacteria to colonize the gut, replicate in host tissues and disseminate to other hosts. Pathogens such as Salmonella, Shigella and enteropathogenic and enterohaemorrhagic (EPEC and EHEC, respectively) Escherichia coli use a type III secretion system (T3SS) to deliver virulence effector proteins into host cells during infection that promote colonization and interfere with antimicrobial host responses1,2,3. Here we report that the T3SS effector NleB1 from EPEC binds to host cell death-domain-containing proteins and thereby inhibits death receptor signalling. Protein interaction studies identified FADD, TRADD and RIPK1 as binding partners of NleB1. NleB1 expressed ectopically or injected by the bacterial T3SS prevented Fas ligand or TNF-induced formation of the canonical death-inducing signalling complex (DISC) and proteolytic activation of caspase-8, an essential step in death-receptor-induced apoptosis. This inhibition depended on the N-acetylglucosamine transferase activity of NleB1, which specifically modified Arg 117 in the death domain of FADD. The importance of the death receptor apoptotic pathway to host defence was demonstrated using mice deficient in the FAS signalling pathway, which showed delayed clearance of the EPEC-like mouse pathogen Citrobacter rodentium and reversion to virulence of an nleB mutant. The activity of NleB suggests that EPEC and other attaching and effacing pathogens antagonize death-receptor-induced apoptosis of infected cells, thereby blocking a major antimicrobial host response.
- Open Access
- 3 June 2013
- Published by Springer Nature in Oncogene
- Vol. 33 (19) , 2540-2546
Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis
Signalling by the toll-like receptor (TLR) family of pathogen recognition receptors has emerged as a key molecular component in the pathogenesis of an increasing number of inflammatory-related cancers, among which gastric cancer rates as the second most lethal cancer world-wide. The myeloid differentiation factor 88 (MyD88) adapter molecule has a critical role in mediating innate immune signalling by members of the TLR and interleukin (IL)-1 families, and has been associated with either pro- or antitumourigenic responses in various cancer models. However, little is known about the in vivo role of MyD88 adapter-like (Mal)/TIR-domain containing adapter protein (TIRAP), which is restricted to facilitating TLR4 and TLR2 signalling. To interrogate the role of these innate immune signalling components in gastric tumourigenesis, here we have employed the spontaneous gastric cancer gp130F/F mouse model, in which TLR2 promotes the growth of gastric tumours. Genetic ablation of Myd88 in gp130F/F mice suppressed tumourigenesis and was associated with increased apoptosis and reduced proliferation in the gastric tumour epithelium, comparable to that observed previously upon deletion of Tlr2 in gp130F/F mice. By contrast, the tumour burden in gp130F/F:Mal−/− mice was equivalent to their gp130F/F littermates. At the molecular level, suppressed tumourigenesis in gp130F/F:Myd88−/− mice correlated with reduced expression and activation of TLR2-regulated protumourigenic genes and signalling pathways, respectively. Consistent with the previously defined non-essential role for TLR2 in gastric tumour inflammation, the extent of inflammatory cell infiltrates in gastric tumours from gp130F/F:Mal−/− and gp130F/F:Myd88−/− mice remained unaltered compared with gp130F/F mice. Collectively, our data reveal a differential, but inflammation-independent, requirement for Mal and MyD88 during TLR2-promoted gastric tumourigenesis.
- 3 June 2013
- Published by Springer Nature in Oncogene
- Vol. 33 (19) , 2540-2546
Open AccessDifferential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis
Signalling by the toll-like receptor (TLR) family of pathogen recognition receptors has emerged as a key molecular component in the pathogenesis of an increasing number of inflammatory-related cancers, among which gastric cancer rates as the second most lethal cancer world-wide. The myeloid differentiation factor 88 (MyD88) adapter molecule has a critical role in mediating innate immune signalling by members of the TLR and interleukin (IL)-1 families, and has been associated with either pro- or antitumourigenic responses in various cancer models. However, little is known about the in vivo role of MyD88 adapter-like (Mal)/TIR-domain containing adapter protein (TIRAP), which is restricted to facilitating TLR4 and TLR2 signalling. To interrogate the role of these innate immune signalling components in gastric tumourigenesis, here we have employed the spontaneous gastric cancer gp130F/F mouse model, in which TLR2 promotes the growth of gastric tumours. Genetic ablation of Myd88 in gp130F/F mice suppressed tumourigenesis and was associated with increased apoptosis and reduced proliferation in the gastric tumour epithelium, comparable to that observed previously upon deletion of Tlr2 in gp130F/F mice. By contrast, the tumour burden in gp130F/F:Mal−/− mice was equivalent to their gp130F/F littermates. At the molecular level, suppressed tumourigenesis in gp130F/F:Myd88−/− mice correlated with reduced expression and activation of TLR2-regulated protumourigenic genes and signalling pathways, respectively. Consistent with the previously defined non-essential role for TLR2 in gastric tumour inflammation, the extent of inflammatory cell infiltrates in gastric tumours from gp130F/F:Mal−/− and gp130F/F:Myd88−/− mice remained unaltered compared with gp130F/F mice. Collectively, our data reveal a differential, but inflammation-independent, requirement for Mal and MyD88 during TLR2-promoted gastric tumourigenesis.
- 1 October 2012
- Published by Elsevier in Cancer Cell
- Vol. 22 (4) , 466-478
STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
- 1 October 2012
- Published by Elsevier in Cancer Cell
- Vol. 22 (4) , 466-478
STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
- 10 May 2011
- Published by Wiley in The Journal of Pathology
- Vol. 225 (2) , 255-264
The molecular pathogenesis of STAT3‐driven gastric tumourigenesis in mice is independent of IL‐17
Chronic activation of the gastric mucosal adaptive immune response is a characteristic trait of gastric cancer. It has recently emerged that a new class of T helper (Th) cells, defined by their ability to produce interleukin (IL)‐17A (Th17), is associated with a host of inflammatory responses, including gastritis. However, the role of these Th17 cells in the pathogenesis of gastric cancer is less clear. To formally address this, we employed gp130F/F mice, which spontaneously develop gastric inflammation‐associated tumours akin to human intestinal‐type gastric cancer. At the molecular level, these tumours demonstrate hyper‐activation of the latent transcription factor signal transducer and activator of transcription (STAT)3 via the IL‐6 cytokine family member, IL‐11. In gp130F/F mice, the generation of Th17 cells, as well as the gastric expression of IL‐17a and other Th17‐related factors (Rorγt, IL‐23), were augmented compared to wild‐type gp130+/+ mice. Consistent with a role for IL‐6 and STAT3 in regulating IL‐17A, increased Th17 generation and gastric expression of Th17‐related factors in gp130F/F mice were reduced to wild‐type levels in gp130F/F:Stat3−/+ mice displaying normalized STAT3 activity, and also in gp130F/F:IL‐6−/− mice. Importantly, genetic ablation of IL‐17A in gp130F/F:IL‐17a−/− mice did not suppress the initiation and growth of gastric tumours. Furthermore, IL‐17A and RORC gene expression was strongly increased in human gastric biopsies from patients with gastritis, but not gastric cancer. Collectively, our data suggest that increased expression of Th17‐related factors does not correlate with the molecular pathogenesis of gastric tumourigenesis. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 10 May 2011
- Published by Wiley in The Journal of Pathology
- Vol. 225 (2) , 255-264
The molecular pathogenesis of STAT3‐driven gastric tumourigenesis in mice is independent of IL‐17
Chronic activation of the gastric mucosal adaptive immune response is a characteristic trait of gastric cancer. It has recently emerged that a new class of T helper (Th) cells, defined by their ability to produce interleukin (IL)‐17A (Th17), is associated with a host of inflammatory responses, including gastritis. However, the role of these Th17 cells in the pathogenesis of gastric cancer is less clear. To formally address this, we employed gp130F/F mice, which spontaneously develop gastric inflammation‐associated tumours akin to human intestinal‐type gastric cancer. At the molecular level, these tumours demonstrate hyper‐activation of the latent transcription factor signal transducer and activator of transcription (STAT)3 via the IL‐6 cytokine family member, IL‐11. In gp130F/F mice, the generation of Th17 cells, as well as the gastric expression of IL‐17a and other Th17‐related factors (Rorγt, IL‐23), were augmented compared to wild‐type gp130+/+ mice. Consistent with a role for IL‐6 and STAT3 in regulating IL‐17A, increased Th17 generation and gastric expression of Th17‐related factors in gp130F/F mice were reduced to wild‐type levels in gp130F/F:Stat3−/+ mice displaying normalized STAT3 activity, and also in gp130F/F:IL‐6−/− mice. Importantly, genetic ablation of IL‐17A in gp130F/F:IL‐17a−/− mice did not suppress the initiation and growth of gastric tumours. Furthermore, IL‐17A and RORC gene expression was strongly increased in human gastric biopsies from patients with gastritis, but not gastric cancer. Collectively, our data suggest that increased expression of Th17‐related factors does not correlate with the molecular pathogenesis of gastric tumourigenesis. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.